Home › NDC Lookup › RxCUI directory › RxCUI 1375954

Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet [D... — RxCUI 1375954

RxNorm drug concept · Semantic branded drug
RxCUI 1375954 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1375954
Official nameDoxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet [Diclegis]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asdoxylamine succinate 10 MG / vit-B6 Hydrochloride 10 MG Delayed Release Oral Tablet [Diclegis]; Diclegis 10 MG / 10 MG Delayed Release Oral Tablet; doxylamine succinate 10 MG / vitamin B6 Hydrochloride 10 MG Delayed Release Oral Tablet [Diclegis]
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)59,900 prescriptions · 26 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Doxylamine and Pyridoxine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes — this is the only FDA-approved oral medication specifically indicated for nausea and vomiting of pregnancy. Multiple large studies, including meta-analyses covering tens of th...
  • Is this medication actually safe to take during pregnancy?
  • Food can significantly reduce how much of the pyridoxine (vitamin B6) component your body actually absorbs — in some studies by around 50%. It also delays when the medication start...
  • Why do I have to take it on an empty stomach?
📖 Read our full Doxylamine and Pyridoxine guide →

🕸️ Concept Web — How Doxylamine succinate 10 MG / pyridoxine hydrochl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet [Diclegis] RxCUI 1375954

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Doxylamine 3642
    • Pyridoxine 684879
    • Doxylamine / pyridoxine 1375947
    • Doxylamine succinate 23665
    • Pyridoxine hydrochloride 203164
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Diclegis 1375949
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Doxylamine / pyridoxine Delayed Release Oral Tablet 1375946
    • Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet 2648926
    • Doxylamine / pyridoxine Oral Product 1375944
    • Doxylamine / pyridoxine Pill 1375945
    • Doxylamine succinate / pyridoxine hydrochloride Oral Product 2659428
    • Doxylamine succinate / pyridoxine hydrochloride Pill 2662894
    • Doxylamine / pyridoxine Delayed Release Oral Tablet [Diclegis] 1375951
    • Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet [Diclegis] 2657734
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 23 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet SCD · 1375948
  • Doxylamine succinate 10 MG SCDC · 1242514
  • Pyridoxine hydrochloride 10 MG SCDC · 349805
  • Doxylamine / pyridoxine Delayed Release Oral Tablet SCDF · 1375946
  • Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet SCDFP · 2648926
  • Doxylamine / pyridoxine Oral Product SCDG · 1375944
  • Doxylamine / pyridoxine Pill SCDG · 1375945
  • Doxylamine succinate / pyridoxine hydrochloride Oral Product SCDGP · 2659428
  • Doxylamine succinate / pyridoxine hydrochloride Pill SCDGP · 2662894

Brand-Name Concepts

  • Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG [Diclegis] SBDC · 1375950
  • Doxylamine / pyridoxine Delayed Release Oral Tablet [Diclegis] SBDF · 1375951
  • Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet [Diclegis] SBDFP · 2657734
  • Diclegis Oral Product SBDG · 1375952
  • Diclegis Pill SBDG · 1375953
  • Diclegis BN · 1375949

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 1375954 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55494-0100-10 100 TABLET, DELAYED RELEASE in 1 BOTTLE (55494-100-10) DICLEGIS Duchesnay USA, Inc. 2013-05-15
55494-0100-99 12 TABLET, DELAYED RELEASE in 1 BOTTLE (55494-100-99) DICLEGIS Duchesnay USA, Inc. 2014-03-28
Observed labelers: Duchesnay USA, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.6776
Range $1.6776–$1.6776 · middle 50% $1.6776–$1.6776 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.